DEROSA LISA | Immunology and Microbiology | Best Researcher Award

Posted on by sciencefather

Assist Prof Dr. DEROSA LISA | Immunology and Microbiology | Best Researcher Award

MD, PhD at Gustave Roussy, France.

Associate Professor Dr. Lisa Derosa is a leading medical oncologist and researcher at Gustave Roussy Cancer Center (GRCC) in France, specializing in tumor immunology and cancer immunotherapy. With an MD from Pisa University and a PhD in Immunology from Paris-Sud University, she has significantly contributed to understanding the immunosuppressive role of antibiotics and the impact of gut microbiota on antitumor immunity. Since 2016, Dr. Derosa has pioneered research in these areas, earning numerous prestigious awards including the Conquer Cancer Foundation ASCO Merit Award and recognitions from ESMO and European Urology. She directs the ClinicoBiome Program at GRCC and co-directs the RHU Clinical Program Grant “Immunolife” and the EU Program Grant “Oncobiome.” Her research skills include clinical trial design, metagenomic analysis, immunological assays, and pharmacodynamic studies, making her a leader in microbiota-centered cancer therapies. Dr. Derosa’s collaborative approach and interdisciplinary projects have resulted in over 100 publications and significant advancements in cancer immunotherapy.

Professional Profiles:

Education

Associate Professor Dr. Lisa Derosa’s educational journey is marked by a series of prestigious degrees and certifications. In 2023, she became an Associate Professor of Immunology at Paris-Saclay University in France. Prior to that, in 2019, she earned her PhD in Immunology from Paris-Sud University and registered as a physician in France the same year. She also obtained a University Diploma in Animal Experimentation Level 1 from Sorbonne University, Paris, in 2018. Her earlier academic achievements include a Diplôme Universitaire Européen de Recherche Translationnelle Et Clinique en Cancérologie (DUERTECC) from Paris-Sud University and a Diplôme d’Université Carcinologie Clíniques (DUC) from Université Paris XI, both in 2016. Dr. Derosa completed her M2 in Pharmacology, Clinical Trial in Oncology at Pisa University in Italy in 2015 and became Board Certified in Medical Oncology from the same university in 2014. She first qualified as a physician in Italy in 2009, following her MD from the School of Medicine at Pisa University in 2008.

Professional Experience

Associate Professor Dr. Lisa Derosa has a distinguished career in medical oncology and cancer immunology. Since 2022, she has been serving as the Co-Coordinator of the RHU IMMUNOLIFE (PIA2) multi-team program project in France and as a member of the Scientific Advisory Board for everImmune. In the same year, she was appointed as an Associate Professor of Immunology at Paris-Saclay University and a Senior Research Associate in the Cancer Immunology Department at Gustave Roussy Cancer Center (GRCC). Dr. Derosa has also been the Clinical Director of the ClinicoBiome Program at GRCC since 2020 and has held the position of Medical Oncology Specialist at GRCC since 2020. From 2017 to 2021, she co-coordinated the PIA2 RHU TORINO LUMIERE project. She has also been a Co-Coordinator of the H2020 ONCOBIOME project since 2019. Prior to these roles, Dr. Derosa served as a clinical attending in the Genitourinary and Lung Department at GRCC from 2019 to 2020 and completed a clinical fellowship in the Genitourinary Medical Oncology Department at GRCC from 2016 to 2019. Before joining GRCC, she was a clinical attending in the Oncology Department at Hospital S. Chiara-Pisa from 2014 to 2016. Additionally, she gained valuable experience as a visiting student at GRCC in 2013 and at the Oncology Department at Ospedali Riuniti di Livorno from 2006 to 2008.

Award and Honors

Associate Professor Dr. Lisa Derosa has received numerous prestigious awards and honors throughout her career, reflecting her significant contributions to oncology and immunology. In 2023, she was honored with the Conquer Cancer Foundation ASCO Merit Award. The previous year, she received an accolade from the European Society for Medical Oncology (ESMO) at their Asia Annual Meeting. In 2021, she was awarded the Best Scientific Paper published on Fundamental Research by European Urology and also received the ASCO Merit Award in Lung Cancer, supported by Frances A. Shepherd. Her exceptional work earned her the EATI Award in 2020. The year 2018 was particularly notable, as she received the Best Paper Award from ESMO YOC, the ESMO Annual Meeting Award, the Early Detection of Cancer Conference Award from ARC, and the Conquer Cancer Foundation ASCO Merit Award. In 2017, she was recognized with multiple Conquer Cancer Foundation ASCO Merit Awards, including the Genitourinary Cancer Merit Award. In 2016, she was the recipient of the 5th Pieter de Mulder Memorial Prize and the ESMO Translational Research Fellowship Award. Her early career was distinguished by the AIOM Award for young researchers in Oncology in 2015, the ESMO Annual Meeting Award in 2014, and the ITT Stage in Oncology Award from the Istituto Toscano Tumori in 2013.

Research Interest

Associate Professor Dr. Lisa Derosa’s research interests lie at the intersection of tumor immunology and cancer immunotherapy, with a particular focus on the immunosuppressive role of antibiotics in cancer treatment and the impact of gut microbiota on antitumor immunity. Since 2016, she has been pioneering research in these areas, exploring how the composition of gut microbiota can regulate the effectiveness of immune checkpoint inhibitors. Her innovative work has led to significant insights into the microbiota’s role in cancer treatment, making her a leading figure in the development of microbiota-centered interventions. Dr. Derosa currently directs the Microbiota-Centered Intervention Program (ClinicoBiome) at Gustave Roussy Cancer Center and co-directs the RHU Clinical Program Grant “Immunolife” as well as the EU Program Grant “Oncobiome.” Her research continues to bridge clinical oncology with translational research, aiming to improve patient outcomes through a deeper understanding of the immune system’s interactions with cancer therapies.

Research Skills

Associate Professor Dr. Lisa Derosa possesses a comprehensive skill set in the field of cancer immunology and immunotherapy, characterized by her expertise in clinical and translational research. She has extensive experience in designing and conducting clinical trials, particularly those investigating the interactions between gut microbiota and immune checkpoint inhibitors. Dr. Derosa is skilled in metagenomic analysis, allowing her to identify microbiome-based biomarkers that predict patient response to immunotherapy. Her proficiency in immunological assays and molecular biology techniques has been instrumental in her research on the immunosuppressive effects of antibiotics and the regulatory role of gut microbiota in antitumor immunity. Additionally, she has a strong background in pharmacodynamic and pharmacokinetic studies, which she has applied in various phase II clinical trials. Dr. Derosa’s ability to integrate clinical data with cutting-edge laboratory research has made her a leader in the development of microbiota-centered cancer therapies. Her collaborative projects often involve multidisciplinary teams, highlighting her skills in project management and scientific communication.

 

Amedeo De Nicolò | Pharmaceutical Science | Best Researcher Award

Posted on by sciencefather

Dr. Amedeo De Nicolò | Pharmaceutical Science | Best Researcher Award

Ricercatore a Tempo Determinato Cat. B at University of Turin, Italy.

Amedeo De Nicolò, born on April 20, 1987, is an Italian researcher currently affiliated with the University of Turin. He holds a PhD in Medicine and Experimental Therapy and a Master’s degree in Cellular and Molecular Biology. De Nicolò specializes in pharmacology, focusing on pharmacokinetics and pharmacogenetics. His research interests include developing bioanalytical methods for Therapeutic Drug Monitoring (TDM) and studying drug interactions and pharmacokinetic/pharmacodynamic evaluations. Throughout his career, he has contributed significantly to clinical pharmacology through various research projects, publications, and participation in international collaborations. In addition to his research, De Nicolò has a strong teaching background, having taught pharmacology courses at the University of Turin and participated in a Master’s program related to biological product control in the industry. He is also an active member of several scientific societies and working groups, including the Italian Society of Pharmacology and the international research consortium VirTUAL.

Professional Profiles:

Education

Amedeo De Nicolò completed his PhD in Medicine and Experimental Therapy from the University of Turin in January 2017. His dissertation focused on the “Pharmacokinetics and Pharmacogenetics of Anti-HCV Treatments,” receiving positive evaluations. Prior to his doctorate, he earned a Master’s degree in Cellular and Molecular Biology, with a Biomedical curriculum, from the same university in October 2011. His master’s thesis titled “Identificazione di Nuovi Parametri Farmacocinetici per la Valutazione Precoce del Rischio di Anemizzazione in Pazienti Sottoposti a Terapia Anti-HCV Standard” was awarded the highest honors, graduating with a score of 110/110 cum laude. Additionally, he holds a Bachelor’s degree in Biological Sciences from the University of Turin, obtained in December 2009. Throughout his academic journey, De Nicolò acquired substantial competencies in biological sciences, clinical pharmacology, laboratory medicine, and statistics. In August 2020, he also achieved professional licensure as a Biologist, further solidifying his qualifications in the field.

Professional Experience

Amedeo De Nicolò is currently a fixed-term researcher (type B) at the University of Turin, specializing in pharmacokinetics and pharmacogenetics. He has been involved in clinical pharmacology research since his internship for his master’s thesis in 2010-2011. From March 2022, he has held his current position at the Department of Medical Sciences, focusing on the development, validation, and application of bioanalytical methods in liquid chromatography for Therapeutic Drug Monitoring (TDM). Prior to this, he was a research fellow from July 2017 to February 2022 at the same institution. During this period, he contributed significantly to pharmacokinetic studies, particularly related to drug-drug interactions and the pharmacokinetic/pharmacodynamic evaluations of antiviral and tuberculosis treatments under the international DERIVE project. De Nicolò has also provided clinical consultancy in interpreting TDM results and has actively participated in the ISO certification processes for biomedical diagnostic kit validations. His extensive experience includes conducting routine drug analysis and providing clinical pharmacological advice since 2012. In addition to his research, he has taught pharmacology modules at the University of Turin for various nursing programs and a master’s course, contributing to academic education alongside his research duties.

Research Interest

Amedeo De Nicolò’s research interests lie primarily in the fields of pharmacokinetics and pharmacogenetics, focusing on clinical pharmacology. His work involves the development, validation, and application of bioanalytical methods using liquid chromatography for Therapeutic Drug Monitoring (TDM). He is particularly interested in studying drug-drug interactions, evaluating pharmacokinetic and pharmacodynamic relationships, and interpreting clinical data through statistical analysis. De Nicolò is also engaged in research related to the pharmacokinetics of antiviral treatments and the intracellular measurement of anti-infective drugs. His involvement in international research consortia, such as VirTUAL and the COVID-19 Mass Spectrometry Coalition, highlights his commitment to advancing knowledge in these areas. Additionally, De Nicolò’s research extends to the standardization of methodological approaches in TDM, contributing to the enhancement of clinical practices and patient care.

Award and Honors

Amedeo De Nicolò has received several notable awards and honors throughout his career, reflecting his significant contributions to the field of clinical pharmacology. He obtained the National Scientific Qualification as Associate Professor in the sector of Pharmacology, Clinical Pharmacology, and Pharmacognosy (05/G1) on November 6, 2018. This achievement recognizes his expertise and leadership in pharmacological research. Furthermore, De Nicolò became a licensed Biologist on August 12, 2020, showcasing his professional qualifications in biological sciences. His work is also distinguished by his active membership in prominent scientific societies, such as the Italian Society of Pharmacology (SIF) and the Italian Society of Clinical Biochemistry (SIBioC), where he continues to contribute to the advancement of pharmacological sciences.

Research skills

Amedeo De Nicolò possesses a robust set of research skills honed through extensive experience in clinical pharmacology. His expertise includes the development, validation, and application of bioanalytical methods in liquid chromatography for Therapeutic Drug Monitoring (TDM), adhering to ISO 9001 and ISO 13485 standards. He excels in pharmacokinetics and pharmacogenetics, focusing on drug interactions, efficacy, and toxicity. De Nicolò is proficient in statistical analysis and the interpretation of clinical and pharmacogenetic data. Additionally, he has a strong background in conducting and coordinating pharmacokinetic studies, including those involving intracellular drug measurements and therapeutic drug monitoring in various medical contexts. His skills are complemented by his ability to write and publish scientific articles, contributing significantly to the body of knowledge in clinical pharmacology.

Publications

  1. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?
    • Authors: Cusato, J., Manca, A., Palermiti, A., Boglione, L., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  2. Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM
    • Authors: Manca, A., Valz, C., Chiara, F., Cusato, J., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  3. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir with Rifampicin
    • Authors: Gausi, K., Mugerwa, H., Siccardi, M., Denti, P., Waitt, C.
    • Year: 2024
    • Citations: 1
  4. Comparative Performance Assessment of Novel Fluorescence Immunoassay POCTs for Measuring Circulating Levels of Vitamin-D
    • Authors: Palermiti, A., Manca, A., Mastrantonio, F., De Nicolò, A., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  5. Pharmacokinetics of tecovirimat in subjects with Mpox
    • Authors: Tempestilli, M., Mondi, A., D’Avolio, A., Vaia, F., Antinori, A.
    • Year: 2024
    • Citations: 0
  6. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
    • Authors: Stroffolini, G., Dodaro, V., De Nicolò, A., D’Avolio, A., Boglione, L.
    • Year: 2024
    • Citations: 0
  7. Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient
    • Authors: Corcione, S., Vita, D., De Nicolò, A., D’Avolio, A., De Rosa, F.G.
    • Year: 2023
    • Citations: 0
  8. Experimental pharmacology in precision medicine
    • Authors: Urbaniak, A., Thummel, K.E., Alade, A.N., Sheppard, D.N., Jarvis, M.F.
    • Year: 2023
    • Citations: 1
  9. Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy
    • Authors: Manca, A., Palermiti, A., Mula, J., De Nicolò, A., D’Avolio, A.
    • Year: 2023
    • Citations: 0
  10. Vitamin D impact in affecting clozapine plasma exposure: A potential contribution of seasonality
    • Authors: Manca, A., Mula, J., Palermiti, A., Cusato, J., D’Avolio, A.
    • Year: 2023
    • Citations: 0